Brian Shields: AI evaluates recent FDA decision
Brian Shields, Creator of KOL Pulse AI, shared on LinkedIn:
“AI evaluates recent FDA decision:
Johnson and Johnson just received FDA approval for the combination of Rybrevant and Lazcluze as first line treatment for EGFRmut lung cancer. This FDA approval was based upon the MARIPOSA clinical trial.
How should clinicians interpret this FDA Approval?
Can data from the Key Opinion Leader Community help?
Enter KOL Pulse AI
Prompt: you are a medical journalist. what are the key opinion leader sentiments regarding the mariposa trial…create a blog post with sourced links to Key opinion leader discussions regarding the mariposa trial...capture positive sentiment. capture negative sentiments and concerns, and create a discussion on the clinical utility of the mariposa trial outcomes for patient care.
KOL Pulse AI response:
Insights from the MARIPOSA Trial: Key Opinions and Clinical Impact
The MARIPOSA trial is making waves in the NSCLC community. Let’s delve into what experts are saying:
Positive Sentiments
Enhanced PFS: Dr. Stephen V Liu notes amivantamab + lazertinib offers superior PFS over osimertinib (23.7 vs. 16.6 months).
High-Risk Subgroups: Dr. Eric Singhi: ‘A path forward to identify biomarkers to help us determine who benefits from 1L combination therapy?’
Concerns
Toxicity: Dr. Liu points out toxicity considerations of combination therapy from Dr. Tony Mok’s presentation
OS Data: Dr. Gilberto Lopes mentions the lack of overall survival data as a limitation in the context of cost and toxicity.
Clinical Utility
Personalized Treatment: Potential for high-risk subgroups benefit from targeted therapies.
First-Line Therapy: Provides an alternative to osimertinib.
Further Research: Emphasizes the need for more studies to include OS data.
The trial combines enthusiasm with caution, presenting advancements but also leaving room for further research.
For more expert insights:
Dr. Rami Manochakian on High-Risk Features.
Dr. Stephen V Liu on Toxicity.
Dr. Gilberto Lopes on OS Data.”
Source: Brian Shields/LinkedIn